Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo tackles meth cravings on demand

NCT ID NCT04791969

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking naltrexone pills only when needed, combined with a smartphone app that offers real-time support, can help men who have sex with men reduce methamphetamine use. Sixty participants were randomly assigned to receive either the drug or a placebo, plus the app, for 12 weeks. The goal was to see if the approach could lower meth-positive urine tests and improve HIV prevention behaviors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
naltrexone (a drug that blocks opioid receptors, used here to reduce meth cravings)
What this could lead to
If it works, this could offer a practical, on-demand treatment to help men who have sex with men cut down meth use and lower their risk of HIV.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drug is taken only as needed, which may not work for all users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

Dec 2021

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * cisgender male (male gender and sex assigned at birth) * age 18-70 years\* (naltrexone's tolerability and safety has been demonstrated among older adults up to age 70) * self-reported condomless anal sex with men or missing Pre-Exposure Prophylaxis or antiretroviral therapy doses due to meth use in the prior three months while under the influence of meth * self-reported meth use at least weekly * mild, moderate or severe meth use disorder * positive meth sample via sweat patch or urine testing during screening * interested in reducing meth use * no current acute illness requiring prolonged medical care * no chronic illness that is likely to progress clinically during trial * able and willing to provide informed consent and adhere to visit schedule * current CD4 count ≥ 200 cells/mm3; or CD4 count of 100-199 cells/mm3 and HIV viral load \< 200 copies/mL (if living with HIV) * baseline complete blood count, total protein, albumin, glucose, alkaline phosphatase, creatinine, blood urea nitrogen test, and electrolytes without clinically significant abnormalities as determined by study clinician in conjunction with symptoms, physical exam, and medical history Exclusion Criteria: * any psychiatric (e.g., depression with suicidal ideation) or medical condition that would preclude safe participation * known allergy or prior adverse reaction to naltrexone * current use of any opioids or a known medical condition which currently requires or may likely require opioid analgesics * opioid-positive urine test at screen/enrollment visits (naltrexone can induce opioid withdrawal) * moderate or severe liver disease (aspartate aminotransferase test, alanine aminotransferase test, or total bilirubin \> 3 times upper limit of normal) * impaired renal function (creatinine clearance \< 60 ml/min) * currently participating in another intervention research study with potential overlap * severe alcohol use disorder as determined by structured clinical interview for DSM-5 criteria * any condition that, in the PI and/or study clinician's judgment interferes with safe participation or adherence to study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methamphetamine use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • San Francisco Department of Public Health

    San Francisco, California, 94102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.